1. Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model
- Author
-
Pamela B. Conley, Oliver Grottke, Necib Akman, Till Braunschweig, Markus Honickel, Rolf Rossaint, and Janet M. Leeds
- Subjects
Male ,Critical Care ,Pyridones ,Swine ,medicine.drug_class ,Hemodynamics ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,Bolus (medicine) ,030202 anesthesiology ,medicine ,Animals ,Blood Coagulation ,Femur fracture ,Multiple Trauma ,business.industry ,Anticoagulant ,Anticoagulants ,medicine.disease ,Polytrauma ,Recombinant Proteins ,Disease Models, Animal ,Anesthesiology and Pain Medicine ,Anesthesia ,Factor Xa ,Pyrazoles ,Apixaban ,business ,Factor Xa Inhibitors ,medicine.drug ,Andexanet alfa - Abstract
BACKGROUND: Andexanet alfa (andexanet) reverses the anticoagulant effects of factor Xa inhibitors, but it has not been assessed in clinical studies for apixaban reversal in trauma. This study evaluated andexanet for reversing apixaban anticoagulation in a porcine polytrauma model. METHODS: Oral apixaban (20 mg q.d., n=21) or placebo (n=7; sham group) was administered to male pigs for 4 days before blunt liver injury and bi-lateral femur fracture. After trauma, animals were randomised 1:1:1 to a single andexanet bolus (1000 mg), a bolus (1000 mg) plus infusion (1200 mg over 2 h), or vehicle (control). Haemodynamic and coagulation variables were monitored for 5 h or until death. The primary endpoint was blood loss. RESULTS: Mean blood loss in sham animals was 472 (standard deviation, 58) ml 12 min after injury and 658 (98) ml at 300 min, with 100% survival. Anticoagulation with apixaban significantly increased blood loss 12 min after injury [888 (133) ml, P
- Published
- 2019
- Full Text
- View/download PDF